Department of Epidemiology and Medical Statistics, Wuhan University, Hubei, China.
The Center for Disease Control and Prevention of Hubei Province, Hubei, China.
Cancer Med. 2017 Sep;6(9):2098-2105. doi: 10.1002/cam4.1158. Epub 2017 Aug 15.
Accumulating papers have demonstrated that microRNAs play an important role in the progression of lung cancer, mainly as oncogenic and tumor suppressive. Therefore, microRNAs may influence the survival of lung cancer patients. In this meta-analysis, we evaluated the role of microRNAs in affecting the overall survival in nonsmall cell lung cancer (NSCLC) patients, which may provide valuable information for the treatment of nonsmall cell lung cancer. We used keywords to retrieve literatures from online databases PUBMED, EMBASE and Web of Science and included 12 studies into our investigation according to pre-set criteria. Then, we analyzed the data with stata13.1 to evaluate the microRNAs role on the prognosis of NSCLC patients. NSCLC patients with higher microRNAs expression levels tend to show lower overall survival. HR (hazard ratio): 2.49, 95% CI (confidence interval): 1.84-3.37. Besides, both oncogenic and tumor suppressive microRNAs have an evident influence on prognosis with HR values of 2.60 (95% CI: 2.12-3.19) and 0.41 (95% CI: 0.05-0.34), respectively. microRNAs, especially from tissue, have an influence on overall survival of NSCLC patients, which indicates that microRNAs could serve as potential prognostic markers for NSCLC and may provide a treatment strategy for advanced NSCLC patients.
越来越多的研究表明 microRNAs 在肺癌的进展中发挥着重要作用,主要作为癌基因和肿瘤抑制因子。因此,microRNAs 可能影响肺癌患者的生存。在这项荟萃分析中,我们评估了 microRNAs 在影响非小细胞肺癌(NSCLC)患者总生存率中的作用,这可能为 NSCLC 的治疗提供有价值的信息。我们使用关键词从在线数据库 PUBMED、EMBASE 和 Web of Science 中检索文献,并根据预设标准纳入了 12 项研究进行分析。然后,我们使用 stata13.1 分析数据,以评估 microRNAs 对 NSCLC 患者预后的作用。microRNAs 表达水平较高的 NSCLC 患者总生存率较低。HR(风险比):2.49,95%CI(置信区间):1.84-3.37。此外,癌基因和肿瘤抑制性 microRNAs 对预后均有明显影响,HR 值分别为 2.60(95%CI:2.12-3.19)和 0.41(95%CI:0.05-0.34)。microRNAs,特别是来自组织的 microRNAs,对 NSCLC 患者的总生存率有影响,这表明 microRNAs 可能作为 NSCLC 的潜在预后标志物,并可能为晚期 NSCLC 患者提供治疗策略。